Table 3.
Comparison of HER2 positive DCIS patient characteristics between our study and the NSABP B-43 trial [4]
| Characteristic | Current Study | NSABP B-43 trial [4] | ||
|---|---|---|---|---|
| HER2-targeted therapy (n = 430) (%) | No HER2-targeted therapy (n = 1497) (%) | HER2-targeted therapy (n = 713) (%) | No HER2-targeted therapy (n = 715) (%) | |
| Age (years) | ||||
| ≤ 50 | 92 (21.4%) | 303 (20.2%) | 161 (22.6%) | 164 (22.9%) |
| > 50 | 338 (78.6%) | 1194 (79.8%) | 552 (77.4%) | 551 (77.1%) |
| Estrogen receptor status | ||||
| Positive | 261 (60.7%) | 992 (66.3%) | 423 (59.3%) | 409 (57.2%) |
| Negative | 169 (39.3%) | 499 (33.3%) | 290 (40.7%) | 304 (42.5%) |
| Not recorded | 0 (0.0%) | 6 (0.4%) | 0 (0.0%) | 2 (0.3%) |
| Grade | ||||
| Well differentiated | 13 (3.0%) | 57 (3.8%) | 10 (1.4%) | 5 (0.7%) |
| Moderately differentiated | 65 (15.1%) | 278 (18.6%) | 108 (15.1%) | 122 (17.1%) |
| Poorly differentiated | 275 (64.0%) | 897 (59.9%) | 595 (83.5%) | 588 (82.2) |
| Not recorded | 77 (17.9%) | 265 (17.7%) | – | – |